Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by TechOneon Aug 13, 2024 2:45pm
688 Views
Post# 36177057

Baxter sells Vantive for 3.8 B to Carlyle

Baxter sells Vantive for 3.8 B to Carlyle
So now that we know Vantive is going to be part of Carlyle, the next question is their contract with Spectral Medical re. EAA (Sepsis Diagnostic) and rollout of (PMX Sepsis Filter) 
 
Vantive actually shows these under "Acute Therapies" and "Near Term Launches" and we know they are working with Spectral so it all boils down to question of timing and Trial completion..  If you own Spectral, I am sure you know all of this..  But here is a reminder.. Slide 11 on their last year's presentation..  
 
Note: at that time, Vantive was shown as Kidneyco (to be split off unit of Baxter, which has now happened) 
 
 
Carlyle's Medical Units are private, large and worth Billions so they are a big beast..  So how all of this shakes out is any one's guess.. 
 
FWIW 

p.s.  These are just notes to some of my cohorts who are holding really large positions and I am kind of stuck to keep them uptodate since they stepped into this because I was harping on it.. After holding it for years, it better pay off or I will have to move..   LOL.. 
<< Previous
Bullboard Posts
Next >>